MedPath
EMA Product

ProQuad

Product approved by European Medicines Agency (EU)

Basic Information

ProQuad

Regulatory Information

EMEA/H/C/000622

Authorised

April 5, 2006

33

July 25, 2024

Company Information

Netherlands

Waarderweg 39 2031 BN Haarlem

Merck Sharp & Dohme BV

Active Substances Detail

virus, live attenuated, measles, virus, live attenuated, mumps, virus, live attenuated, rubella, virus, live attenuated, varicella

Detailed Information

Therapeutic Indication

### Therapeutic indication ProQuad is indicated for simultaneous vaccination against measles, mumps, rubella and varicella in individuals from 12 months of age. ProQuad can be administered to individuals from 9 months of age under special circumstances (e.g., to conform with national vaccination schedules, outbreak situations, or travel to a region with high prevalence of measles.

Overview Summary

ProQuad is a vaccine against measles, mumps, rubella, and varicella (chickenpox). ProQuad is given to children from 12 months of age to help protect them against measles, mumps, rubella, and chickenpox. ProQuad may also be given to children from 9 months of age in certain situations, for example as part of a national vaccination programme, during an outbreak or for travel to a region where measles is common.

© Copyright 2025. All Rights Reserved by MedPath